{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,22]],"date-time":"2026-01-22T18:50:44Z","timestamp":1769107844910,"version":"3.49.0"},"reference-count":17,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,9,1]],"date-time":"2021-09-01T00:00:00Z","timestamp":1630454400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2021,4,2]],"date-time":"2021-04-02T00:00:00Z","timestamp":1617321600000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006920","name":"University of Pennsylvania","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100006920","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"National Eye Institute","doi-asserted-by":"publisher","award":["R01 EY026972"],"award-info":[{"award-number":["R01 EY026972"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100007489","name":"Bausch and Lomb","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007489","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["jaadinternational.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["JAAD International"],"published-print":{"date-parts":[[2021,9]]},"DOI":"10.1016\/j.jdin.2021.03.009","type":"journal-article","created":{"date-parts":[[2021,4,29]],"date-time":"2021-04-29T22:01:21Z","timestamp":1619733681000},"page":"1-9","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":7,"special_numbering":"C","title":["Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study"],"prefix":"10.1016","volume":"4","author":[{"given":"John S.","family":"Barbieri","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vatinee Y.","family":"Bunya","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mina","family":"Massaro-Giordano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"David J.","family":"Margolis","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.jdin.2021.03.009_bib2","doi-asserted-by":"crossref","first-page":"459","DOI":"10.1111\/bjd.17869","article-title":"Conjunctivitis in dupilumab clinical trials","volume":"181","author":"Akinlade","year":"2019","journal-title":"Br J Dermatol"},{"issue":"24","key":"10.1016\/j.jdin.2021.03.009_bib3","doi-asserted-by":"crossref","first-page":"2335","DOI":"10.1056\/NEJMoa1610020","article-title":"Two phase 3 trials of dupilumab versus placebo in atopic dermatitis","volume":"375","author":"Simpson","year":"2016","journal-title":"N Engl J Med"},{"issue":"5","key":"10.1016\/j.jdin.2021.03.009_bib4","doi-asserted-by":"crossref","first-page":"1083","DOI":"10.1111\/bjd.16156","volume":"178","author":"de Bruin-Weller","year":"2018","journal-title":"Br J Dermatol"},{"issue":"5","key":"10.1016\/j.jdin.2021.03.009_bib5","doi-asserted-by":"crossref","first-page":"855","DOI":"10.1016\/j.jaad.2017.06.153","article-title":"Efficacy and safety of ixekizumab for the treatment of moderate-to-severe plaque psoriasis: results through 108 weeks of a randomized, controlled phase 3 clinical trial (UNCOVER-3)","volume":"77","author":"Blauvelt","year":"2017","journal-title":"J Am Acad Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2021.03.009_bib6","doi-asserted-by":"crossref","first-page":"300","DOI":"10.1016\/j.jaad.2020.09.084","article-title":"Dupilumab and the risk of conjunctivitis and serious infection in patients with atopic dermatitis: a propensity score-matched cohort study","volume":"84","author":"Schneeweiss","year":"2021","journal-title":"J Am Acad Dermatol"},{"issue":"10","key":"10.1016\/j.jdin.2021.03.009_bib7","doi-asserted-by":"crossref","first-page":"1208","DOI":"10.1001\/jamadermatol.2018.2690","article-title":"Risk factors for dupilumab-associated conjunctivitis in patients with atopic dermatitis","volume":"154","author":"Treister","year":"2018","journal-title":"JAMA Dermatol"},{"issue":"2","key":"10.1016\/j.jdin.2021.03.009_bib8","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1111\/ijd.14573","article-title":"Real-world experience of dupilumab treatment for atopic dermatitis in adults: a retrospective analysis of patients' records","volume":"59","author":"Wang","year":"2020","journal-title":"Int J Dermatol"},{"issue":"3","key":"10.1016\/j.jdin.2021.03.009_bib9","doi-asserted-by":"crossref","first-page":"201","DOI":"10.18176\/jiaci.0481","article-title":"Dupilumab-associated conjunctivitis in patients with atopic dermatitis: a multicenter real-life experience","volume":"30","author":"Nettis","year":"2020","journal-title":"J Investig Allergol Clin Immunol"},{"issue":"1","key":"10.1016\/j.jdin.2021.03.009_bib10","doi-asserted-by":"crossref","first-page":"172","DOI":"10.1111\/jdv.16724","article-title":"Incidence and risk factors for dupilumab associated ocular adverse events: a real-life prospective study","volume":"35","author":"Touhouche","year":"2021","journal-title":"J Eur Acad Dermatol Venereol"},{"issue":"4","key":"10.1016\/j.jdin.2021.03.009_bib11","doi-asserted-by":"crossref","first-page":"578","DOI":"10.1016\/j.alit.2020.04.002","article-title":"Dupilumab efficacy and safety in Japanese patients with uncontrolled, moderate-to-severe asthma in the phase 3 Liberty ASTHMA QUEST study","volume":"69","author":"Tohda","year":"2020","journal-title":"Allergol Int"},{"issue":"26","key":"10.1016\/j.jdin.2021.03.009_bib12","doi-asserted-by":"crossref","first-page":"2475","DOI":"10.1056\/NEJMoa1804093","article-title":"Efficacy and safety of dupilumab in glucocorticoid-dependent severe asthma","volume":"378","author":"Rabe","year":"2018","journal-title":"N Engl J Med"},{"issue":"9596","key":"10.1016\/j.jdin.2021.03.009_bib14","doi-asserted-by":"crossref","first-page":"1453","DOI":"10.1016\/S0140-6736(07)61602-X","article-title":"The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies","volume":"370","author":"von Elm","year":"2007","journal-title":"Lancet"},{"issue":"4","key":"10.1016\/j.jdin.2021.03.009_bib15","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1007\/s40268-019-00288-x","article-title":"A clinician's guide to the recognition and management of dupilumab-associated conjunctivitis","volume":"19","author":"Agnihotri","year":"2019","journal-title":"Drugs R D"},{"issue":"2","key":"10.1016\/j.jdin.2021.03.009_bib16","doi-asserted-by":"crossref","first-page":"67","DOI":"10.5005\/jp-journals-10028-1226","article-title":"Steroid-induced glaucoma: an avoidable irreversible blindness","volume":"11","author":"Phulke","year":"2017","journal-title":"J Curr Glaucoma Pract"},{"issue":"3","key":"10.1016\/j.jdin.2021.03.009_bib17","doi-asserted-by":"crossref","first-page":"485","DOI":"10.1007\/s40123-019-0191-9","article-title":"Ocular surface diseases induced by dupilumab in severe atopic dermatitis","volume":"8","author":"Maudinet","year":"2019","journal-title":"Ophthalmol Ther"},{"issue":"2","key":"10.1016\/j.jdin.2021.03.009_bib18","doi-asserted-by":"crossref","first-page":"753","DOI":"10.1016\/j.jaip.2018.10.055","article-title":"Letter regarding \u201cConjunctivitis occurring in atopic dermatitis patients treated with dupilumab-clinical characteristics and treatment.\u201d","volume":"7","author":"Rial","year":"2019","journal-title":"J Allergy Clin Immunol Pract"},{"issue":"7","key":"10.1016\/j.jdin.2021.03.009_bib19","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1111\/jdv.15608","article-title":"Conjunctivitis in atopic dermatitis patients with and without dupilumab therapy\u2013international eczema council survey and opinion","volume":"33","author":"Thyssen","year":"2019","journal-title":"J Eur Acad Dermatol Venereol"}],"container-title":["JAAD International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328721000237?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2666328721000237?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,12]],"date-time":"2025-11-12T20:59:02Z","timestamp":1762981142000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2666328721000237"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,9]]},"references-count":17,"alternative-id":["S2666328721000237"],"URL":"https:\/\/doi.org\/10.1016\/j.jdin.2021.03.009","relation":{},"ISSN":["2666-3287"],"issn-type":[{"value":"2666-3287","type":"print"}],"subject":[],"published":{"date-parts":[[2021,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Encounters and medication use for ocular surface disorders among patients treated with dupilumab: A cohort study","name":"articletitle","label":"Article Title"},{"value":"JAAD International","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jdin.2021.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 by the American Academy of Dermatology, Inc. Published by Elsevier Inc.","name":"copyright","label":"Copyright"}]}}